2 terminated, 1 active not recruiting, 1 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Terminated 2 |
Follow INCB057643: new trials by email Literature Review of INCB057643 trials Research Report on INCB057643
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants INCB057643 - Healthy Volunteers | Phase 1 | Completed | Incyte Corporation | 48 | 2025-05-12 | 2025-06-11 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms INCB057643, Ruxolitinib - Myelofibrosis, Myelodysplastic Syndrome | Phase 1 | Active not recruiting | Incyte Corporation | 140 | 2021-02-23 | 2026-04-01 |
| Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Azacitidine, Pembrolizumab, Epacadostat - Solid Tumors, Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 70 | 2017-02-27 | 2025-10-21 |
| Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies INCB057643, Gemcitabine, Paclitaxel - Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 137 | 2016-05-18 | 2025-10-21 |
Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Primary Myelofibrosis (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Leukemia (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
United States (4) · Spain (2) · United Kingdom (2) · Belgium (1) · Canada (1) · China (1) · Finland (1) · France (1) · Italy (1) · Japan (1)
Fred Zheng, MD, PhD (1) · Kevin O'Hayer, MD (1)
2016 (1), 2017 (1), 2023 (1)